Roquefort Therapeutics (LON:ROQ) Trading Up 18.5% – Still a Buy?

Roquefort Therapeutics plc (LON:ROQ)’s share price was up 18.5% on Friday . The stock traded as high as GBX 1.60 ($0.02) and last traded at GBX 1.60 ($0.02). Approximately 944,897 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 2,248,070 shares. The stock had previously closed at GBX 1.35 ($0.02).

Roquefort Therapeutics Trading Up 18.5%

The firm’s 50-day simple moving average is GBX 1.67 and its 200-day simple moving average is GBX 2.46. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The firm has a market capitalization of £2.04 million, a PE ratio of -1.32 and a beta of 0.05.

Roquefort Therapeutics (LON:ROQ) last posted its quarterly earnings results on Wednesday, April 30th. The company reported GBX (0.75) (($0.01)) earnings per share for the quarter. Roquefort Therapeutics had a negative return on equity of 29.57% and a negative net margin of 57,057.07%.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.